[Treatment of chronic hepatitis B].

[1]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[2]  F. Zoulim,et al.  Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  T. Asselah,et al.  The current status of antiviral therapy of chronic hepatitis B. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[4]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[5]  T. Asselah,et al.  Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. , 2005, Journal of hepatology.

[6]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[7]  M. Yuen,et al.  Telbivudine: an upcoming agent for chronic hepatitis B , 2005, Expert review of anti-infective therapy.

[8]  George Kitis,et al.  Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine , 2005, Hepatology.

[9]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[10]  L. Roberts,et al.  The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. , 2005, Journal of hepatology.

[11]  V. Wong,et al.  A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.

[12]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[13]  T. Berg,et al.  Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection , 2004, Hepatology.

[14]  F. Zoulim.  Antiviral Therapy of Chronic Hepatitis B: Can We Clear the Virus and Prevent Drug Resistance? , 2004, Antiviral chemistry & chemotherapy.

[15]  Ching-lung Lai,et al.  Four years of lamivudine treatment in Chinese patients with chronic hepatitis B , 2004, Journal of gastroenterology and hepatology.

[16]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[17]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[18]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[19]  P. Marcellin,et al.  A phase II dose‐escalating trial of clevudine in patients with chronic hepatitis B , 2004, Hepatology.

[20]  D. Cooper,et al.  Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. , 2004, The Journal of infectious diseases.

[21]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[22]  R. Chung,et al.  Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  Man-Fung Yuen,et al.  Viral hepatitis B , 2003, The Lancet.

[24]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[25]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[26]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[27]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[28]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[29]  Sung Gyoo Park,et al.  Fidelity of hepatitis B virus polymerase. , 2003, European journal of biochemistry.

[30]  J. Sung,et al.  A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis , 2003 .

[31]  M. Colombo,et al.  Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy , 2003, Hepatology.

[32]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[33]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[34]  T. Berg,et al.  Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. , 2003, Gastroenterology.

[35]  P. Tebas,et al.  Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. , 2002, The Journal of infectious diseases.

[36]  S. Hadziyannis,et al.  Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease , 2002, Hepatology.

[37]  E. Holmes,et al.  A Revised Evolutionary History of Hepatitis B Virus (HBV) , 2002, Journal of Molecular Evolution.

[38]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.

[39]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[40]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[41]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[42]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[43]  S. Sarafianos,et al.  Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.

[44]  S. Hadziyannis,et al.  The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .

[45]  A. Lok,et al.  Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy , 2000, Hepatology.

[46]  L. Stuyver,et al.  Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B , 2000, Hepatology.

[47]  J. Hoofnagle,et al.  Long‐term therapy of chronic hepatitis B with lamivudine , 2000, Hepatology.

[48]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[49]  C. Gibbs,et al.  Combination therapy with lamivudine and famciclovir for chronic hepatitis B–infected Chinese patients: A viral dynamics study , 2000, Hepatology.

[50]  Y. Liaw,et al.  Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 2000, Gastroenterology.

[51]  M. Rizzetto,et al.  Response of pre‐core mutant chronic hepatitis B infection to lamivudine , 2000, Journal of medical virology.

[52]  A. Dhillon,et al.  Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial , 2000, Gut.

[53]  Nicholson,et al.  Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir , 2000, Journal of viral hepatitis.

[54]  T. Santantonio,et al.  Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. , 2000, Journal of hepatology.

[55]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[56]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[57]  M. Buti,et al.  Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. , 1999, Hepatology.

[58]  K. Krogsgaard.  The long‐term effect of treatment with interferon‐α2a in chronic hepatitis B , 1998 .

[59]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[60]  A. Nicoll,et al.  REVIEW: Present and future directions in the treatment of chronic hepatitis B infection , 1997, Journal of gastroenterology and hepatology.

[61]  A. Morabito,et al.  A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum , 1997, Hepatology.

[62]  J. Hoofnagle,et al.  Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. , 1997, Gastroenterology.

[63]  G. Fattovich,et al.  Long‐term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa , 1997, Hepatology.

[64]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[65]  D. Häussinger,et al.  Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. , 1996, The New England journal of medicine.

[66]  E. Schiff,et al.  A preliminary trial of lamivudine for chronic hepatitis B infection. , 1995, The New England journal of medicine.

[67]  A. Lok,et al.  Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. , 1993, Gastroenterology.

[68]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[69]  I. Lauder,et al.  A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. , 1992, Gastroenterology.

[70]  M. Rugge,et al.  A randomized controlled trial of lymphoblastoid interferon‐α in patients with chronic hepatitis B lacking HBeAg , 1992, Hepatology.

[71]  M. Milella,et al.  Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. , 1992, Journal of hepatology.

[72]  M. Loriot,et al.  Demonstration of hepatitis B virus DNA by polymerase chain reaction in the serum and the liver after spontaneous or therapeutically induced HBeAg to anti‐HBe or HBsAg to Anti‐HBs seroconversion in patients with chronic hepatitis B , 1992, Hepatology.

[73]  J. Hoofnagle,et al.  Long-term remission of chronic hepatitis B after alpha-interferon therapy. , 1991, Annals of internal medicine.

[74]  E. Schiff,et al.  A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .

[75]  M. Loriot,et al.  Persistence of hepatitis B virus DNA demonstrated by polymerase chain reaction in serum and liver after loss of HBsAg induced by antiviral therapy. , 1990, Annals of internal medicine.

[76]  H. Thomas,et al.  Which patients with chronic hepatitis B virus infection will respond to α‐interferon therapy? A statistical analysis of predictive factors , 1989, Hepatology.

[77]  D. Samuel.  Management of hepatitis B in liver transplantation patients. , 2004, Seminars in liver disease.

[78]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[79]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[80]  T. Poynard,et al.  Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. , 2003, Journal of hepatology.

[81]  H. Thomas,et al.  Mechanisms of action of interferon and nucleoside analogues. , 2003, Journal of hepatology.

[82]  A. Makris,et al.  Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.